Raymond James & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $21.2K | Sell |
23,437
-2,289
| -9% | -$2.07K | ﹤0.01% | 3891 |
|
|
2024
Q2 | $25.7K | Buy |
25,726
+5,539
| +27% | +$5.52K | ﹤0.01% | 3821 |
|
|
2024
Q1 | $29.9K | Hold |
20,187
| – | – | ﹤0.01% | 3802 |
|
|
2023
Q4 | $22K | Sell |
20,187
-3,582
| -15% | -$3.9K | ﹤0.01% | 3712 |
|
|
2023
Q3 | $28K | Hold |
23,769
| – | – | ﹤0.01% | 3674 |
|
|
2023
Q2 | $33.5K | Buy |
23,769
+2,596
| +12% | +$3.66K | ﹤0.01% | 3684 |
|
|
2023
Q1 | $31.8K | Buy |
21,173
+1,000
| +5% | +$1.5K | ﹤0.01% | 3719 |
|
|
2022
Q4 | $23.6K | Sell |
20,173
-942
| -4% | -$1.1K | ﹤0.01% | 3707 |
|
|
2022
Q3 | $24K | Buy |
21,115
+1,502
| +8% | +$1.71K | ﹤0.01% | 3717 |
|
|
2022
Q2 | $31K | Hold |
19,613
| – | – | ﹤0.01% | 3768 |
|
|
2022
Q1 | $30K | Buy |
19,613
+2,800
| +17% | +$4.28K | ﹤0.01% | 3862 |
|
|
2021
Q4 | $41K | Hold |
16,813
| – | – | ﹤0.01% | 3889 |
|
|
2021
Q3 | $42K | Hold |
16,813
| – | – | ﹤0.01% | 3856 |
|
|
2021
Q2 | $48K | Sell |
16,813
-44
| -0.3% | -$126 | ﹤0.01% | 3843 |
|
|
2021
Q1 | $40K | Sell |
16,857
-3,021
| -15% | -$7.17K | ﹤0.01% | 3776 |
|
|
2020
Q4 | $35K | Buy |
19,878
+8,600
| +76% | +$15.1K | ﹤0.01% | 3575 |
|
|
2020
Q3 | $11K | Hold |
11,278
| – | – | ﹤0.01% | 3447 |
|
|
2020
Q2 | $10K | Hold |
11,278
| – | – | ﹤0.01% | 3381 |
|
|
2020
Q1 | $9K | Sell |
11,278
-1,000
| -8% | -$798 | ﹤0.01% | 3373 |
|
|
2019
Q4 | $11K | Buy |
12,278
+65
| +0.5% | +$58 | ﹤0.01% | 3537 |
|
|
2019
Q3 | $12K | Hold |
12,213
| – | – | ﹤0.01% | 3470 |
|
|
2019
Q2 | $13K | Buy |
12,213
+39
| +0.3% | +$42 | ﹤0.01% | 3485 |
|
|
2019
Q1 | $16K | Buy |
+12,174
| New | +$16K | ﹤0.01% | 3464 |
|
|
2017
Q2 | – | Sell |
-36,507
| Closed | -$110K | – | 3223 |
|
|
2017
Q1 | $110K | Buy |
+36,507
| New | +$110K | ﹤0.01% | 3021 |
|